Table 4 Genotype distribution and allelic frequency of IL-6 (−174G/C) in controls and patients with ovarian cancer
Cytokine gene | Control (N = 48) | Ovarian cancer (N = 48) | P value | OR (95% CI) | AAIC | BBIC |
|---|---|---|---|---|---|---|
IL-6 (− 174 G > C) Genotype (N, %) | ||||||
Codominant model (GC, CC vs. GG) GG | 34 (70.8%) | 23 (47.9%) | P < 0.001 | 1.00 | 107.3 | 112.4 |
G/C | 13 (27.1%) | 3 (6.2%) | P < 0.001 | 0.34 (0.09–1.33) | ||
C/C | 1 (2.1%) | 22 (45.8%) | P < 0.001 | 32.52 (4.09–258.36) | ||
Dominant model (GC+CC vs. GG) GC+CC | 14 (29.2%) | 25 (52.1%) | P < 0.05 | 2.64 (1.14–6.12) | ||
Recessive model (CC vs. GG+GC) GG+GC | 47 (97.9%) | 26 (54.2%) | P < 0.001 | 1.00 | ||
C/C | 1 (2.1%) | 22 (45.8%) | P < 0.001 | 39.77 (5.07–312.10) | ||
Allele frequency (N, %) | ||||||
G | 81 (84.0%) | 49 (51.0%) | P < 0.001 | 0.193 (0.098–0.381) | ||
C | 15 (16.0%) | 47 (49.0%) | P < 0.001 | 5.180 (2.622–10.233) | ||